Doris K Hansen

39PUBLICATIONS
167CO-AUTHORS
Medical infection agents (incl. prions)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (39)

|Oct 26, 2026
Temporal trends in infectious risk among multiple myeloma patients treated with daratumumab: A meta-analysis.

|Oct 23, 2026
Impact of extramedullary plasmacytoma on outcomes in patients with relapsed refractory multiple myeloma treated with talquetamab: U.S. Myeloma Immunotherapy Consortium.

|Jul 21, 2026
Chronic graft-versus-host disease after PTCy-based prophylaxis vs non-PTCy prophylaxis.

|Jul 17, 2026
A novel severe toxicity-free, and progression-free survival endpoint predicts outcomes after CD19 chimeric antigen receptor-T cell therapy in large B-cell lymphoma.

|Jul 08, 2026
Rapid peak cilta-cel expansion is associated with delayed neurotoxicity in multiple myeloma.

|Jul 02, 2026
Real-world outcomes with BCMA- and GPRC5D-targeting bispecific antibodies in plasma cell leukemia.

Pageof 7

Frequent Collaborators

20 joint publications

Omar Castaneda-Puglianini

20 joint publications

Surbhi Sidana

17 joint publications

Jack Khouri

16 joint publications

Larry D Anderson